Therapy News and Research

RSS

State-funded multidisciplinary model improves care for adults with neurodevelopmental disorders

Adults with autism spectrum disorder (ASD) and other neurodevelopmental disorders (NDDs) often lose access to specialized care once they age out of pediatric services.

9 Dec 2025

SwRI and Trinity researchers work on next-generation intranasal therapy for PTSD

Southwest Research Institute (SwRI) and Trinity University are developing an intranasal (IN) drug-device combination to treat post-traumatic stress disorder (PTSD).

9 Dec 2025

Research ushers in a new era of hope for patients with primary immune thrombocytopenia

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia (ITP), an autoimmune disorder that can cause life-threatening bleeding, were able to maintain safe platelet counts without serious bleeding episodes for at least one year.

9 Dec 2025

Study uncovers how the body's bile acids bind to block C. diff's most dangerous toxin

In a major step towards a precision therapy for Clostridioides difficile (C. diff) infection, researchers at The Hospital for Sick Children (SickKids) have uncovered how the body's bile acids bind to block C. diff's most dangerous toxin.

9 Dec 2025

New antibody shows ability to overcome treatment resistance in blood cancers and solid tumors

In a new preclinical study, researchers from The University of Texas MD Anderson Cancer Center developed an antibody therapy called 77A that showed an ability to overcome treatment resistance in blood cancers, such as myeloma and lymphoma, as well as solid tumors.

9 Dec 2025

Patients receiving T-cell redirecting therapies can safely be monitored at home

Patients who receive T-cell redirecting therapies are typically hospitalized for several days after treatment to watch for side effects.

9 Dec 2025

Genome-edited immune cell therapy shows promise for treating aggressive blood cancer

A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street Hospital (GOSH), has shown promising results in helping children and adults fight a rare and aggressive form of blood cancer called T-cell acute lymphoblastic leukemia (T-ALL).

8 Dec 2025

Powerful prognostic marker could enable early identification of high-risk cancer patients

Aggressive T-cell lymphoma is a rare and devastating form of blood cancer with a very low five-year survival rate.

8 Dec 2025

Combination therapy may boost survival for people with aggressive lymphoma

A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may sharply boost one-year progression-free survival for people with aggressive lymphoma.

8 Dec 2025

Lymphocyte levels help predict outcomes after CAR T-cell therapy in non-Hodgkin lymphoma

Measuring the lymphocytes - white blood cells that fight infection - in a patient's blood can be used to predict outcomes in non-Hodgkin lymphoma patients who receive CAR T-cell therapy, according to research from physicians at Fox Chase Cancer Center and Temple Health.

8 Dec 2025

Timing of genetic mutation dictates childhood leukemia aggressiveness

A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same leukemia-causing gene mutation can have dramatically different outcomes: it depends on when in development the mutation first occurs.

8 Dec 2025

Targeted approach of immunotherapy improves sepsis outcomes

Immunotherapy for sepsis is effective when doctors tailor the treatment precisely to the patient's immune system condition.

8 Dec 2025

Serious side effects after CAR T cell therapy for multiple myeloma share a common immune root cause

Serious side effects, including neurotoxicity and intestinal inflammation, that appear weeks or months after patients receive CAR T cell therapy for multiple myeloma share a common immune root cause, are associated with high rates of death unrelated to cancer relapse-primarily infection-and may be avoidable.

8 Dec 2025

New combination treatment offers significant benefits for people with recurring grade 3 astrocytoma

Huntsman Cancer Institute at the University of Utah (the U) participated in a clinical trial that found that a new combination treatment plan helped people with recurring grade 3 astrocytoma, an aggressive form of brain cancer, live longer.

8 Dec 2025

Young Australians are staying on antidepressants for longer than ever

Long-term antidepressant use in Australia increased steadily between 2014 and 2023, with the largest relative rise seen among adolescents and young adults aged 10 to 24 years. Treatment duration also lengthened over time, while apparent dose reduction efforts remained limited, raising concerns about deprescribing practices.

7 Dec 2025

Chemotherapy-free combination treatment outperforms traditional regimens in patients with Ph+ ALL

A chemotherapy-free combination treatment outperformed a combination of targeted therapy and chemotherapy among patients with Ph+ acute lymphoblastic leukemia (ALL) in a new study.

7 Dec 2025

Virtual diet and exercise program shows promise in reducing lymphoma treatment side effects

Patients undergoing treatment for lymphoma often experience adverse side effects that can be so severe that they stop or slow treatment.

7 Dec 2025

Evidence grows for pirtobrutinib as a safer and effective alternative for CLL and SLL

Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate in the first head-to-head comparison with ibrutinib, a covalent BTK inhibitor.

7 Dec 2025

Aza-ven shows superior outcomes compared to induction chemotherapy in AML patients

In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen of azacitidine and venetoclax compared with conventional induction chemotherapy.

7 Dec 2025

New trial shows major survival gains with epcoritamab added to standard R2 therapy

In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction in the risk of death or disease progression if they received epcoritamab in addition to the standard second-line regimen versus the standard regimen alone.

7 Dec 2025

Previous
1
...
92
93
94
95
96
97
98
...
2932
Next

Therapy News and Research

State-funded multidisciplinary model improves care for adults with neurodevelopmental disorders

SwRI and Trinity researchers work on next-generation intranasal therapy for PTSD

Research ushers in a new era of hope for patients with primary immune thrombocytopenia

Study uncovers how the body's bile acids bind to block C. diff's most dangerous toxin

New antibody shows ability to overcome treatment resistance in blood cancers and solid tumors

Patients receiving T-cell redirecting therapies can safely be monitored at home

Genome-edited immune cell therapy shows promise for treating aggressive blood cancer

Powerful prognostic marker could enable early identification of high-risk cancer patients

Combination therapy may boost survival for people with aggressive lymphoma

Lymphocyte levels help predict outcomes after CAR T-cell therapy in non-Hodgkin lymphoma

Timing of genetic mutation dictates childhood leukemia aggressiveness

Targeted approach of immunotherapy improves sepsis outcomes

Serious side effects after CAR T cell therapy for multiple myeloma share a common immune root cause

New combination treatment offers significant benefits for people with recurring grade 3 astrocytoma

Young Australians are staying on antidepressants for longer than ever

Chemotherapy-free combination treatment outperforms traditional regimens in patients with Ph+ ALL

Virtual diet and exercise program shows promise in reducing lymphoma treatment side effects

Evidence grows for pirtobrutinib as a safer and effective alternative for CLL and SLL

Aza-ven shows superior outcomes compared to induction chemotherapy in AML patients

New trial shows major survival gains with epcoritamab added to standard R2 therapy

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News